drugset / Trial / NCT00003431
Flt3L in Treating Patients With Metastatic Colorectal Cancer
Treatment
Summary
RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
Timeline
- Start
- 1998-06
- Primary completion
- —
- Completion
- 2001-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | flt3 ligand | Protein / enzyme biologic | — | Subcutaneous |